Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ig Enhancers Increase RNA Polymerase II Stalling at Somatic Hypermutation Target Sequences

A. Tarsalainen, Y. Maman, FL. Meng, MK. Kyläniemi, A. Soikkeli, P. Budzyńska, JJ. McDonald, F. Šenigl, FW. Alt, DG. Schatz, J. Alinikula

. 2022 ; 208 (1) : 143-154. [pub] 20211203

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011513

Grantová podpora
R01 AI127642 NIAID NIH HHS - United States
T32 AI007019 NIAID NIH HHS - United States
UL1 TR001863 NCATS NIH HHS - United States

Somatic hypermutation (SHM) drives the genetic diversity of Ig genes in activated B cells and supports the generation of Abs with increased affinity for Ag. SHM is targeted to Ig genes by their enhancers (diversification activators [DIVACs]), but how the enhancers mediate this activity is unknown. We show using chicken DT40 B cells that highly active DIVACs increase the phosphorylation of RNA polymerase II (Pol II) and Pol II occupancy in the mutating gene with little or no accompanying increase in elongation-competent Pol II or production of full-length transcripts, indicating accumulation of stalled Pol II. DIVAC has similar effect also in human Ramos Burkitt lymphoma cells. The DIVAC-induced stalling is weakly associated with an increase in the detection of ssDNA bubbles in the mutating target gene. We did not find evidence for antisense transcription, or that DIVAC functions by altering levels of H3K27ac or the histone variant H3.3 in the mutating gene. These findings argue for a connection between Pol II stalling and cis-acting targeting elements in the context of SHM and thus define a mechanistic basis for locus-specific targeting of SHM in the genome. Our results suggest that DIVAC elements render the target gene a suitable platform for AID-mediated mutation without a requirement for increasing transcriptional output.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011513
003      
CZ-PrNML
005      
20220506130026.0
007      
ta
008      
220425s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.4049/jimmunol.2100923 $2 doi
035    __
$a (PubMed)34862258
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tarsalainen, Alina $u Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland $1 https://orcid.org/0000000271555316
245    10
$a Ig Enhancers Increase RNA Polymerase II Stalling at Somatic Hypermutation Target Sequences / $c A. Tarsalainen, Y. Maman, FL. Meng, MK. Kyläniemi, A. Soikkeli, P. Budzyńska, JJ. McDonald, F. Šenigl, FW. Alt, DG. Schatz, J. Alinikula
520    9_
$a Somatic hypermutation (SHM) drives the genetic diversity of Ig genes in activated B cells and supports the generation of Abs with increased affinity for Ag. SHM is targeted to Ig genes by their enhancers (diversification activators [DIVACs]), but how the enhancers mediate this activity is unknown. We show using chicken DT40 B cells that highly active DIVACs increase the phosphorylation of RNA polymerase II (Pol II) and Pol II occupancy in the mutating gene with little or no accompanying increase in elongation-competent Pol II or production of full-length transcripts, indicating accumulation of stalled Pol II. DIVAC has similar effect also in human Ramos Burkitt lymphoma cells. The DIVAC-induced stalling is weakly associated with an increase in the detection of ssDNA bubbles in the mutating target gene. We did not find evidence for antisense transcription, or that DIVAC functions by altering levels of H3K27ac or the histone variant H3.3 in the mutating gene. These findings argue for a connection between Pol II stalling and cis-acting targeting elements in the context of SHM and thus define a mechanistic basis for locus-specific targeting of SHM in the genome. Our results suggest that DIVAC elements render the target gene a suitable platform for AID-mediated mutation without a requirement for increasing transcriptional output.
650    _2
$a zvířata $7 D000818
650    _2
$a rozmanitost protilátek $7 D000916
650    _2
$a ptačí proteiny $x genetika $x metabolismus $7 D030161
650    _2
$a podskupiny B-lymfocytů $x imunologie $7 D016175
650    _2
$a Burkittův lymfom $x genetika $x imunologie $7 D002051
650    _2
$a kur domácí $7 D002645
650    _2
$a cytidindeaminasa $x genetika $7 D003564
650    _2
$a zesilovače transkripce $x genetika $7 D004742
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny $x genetika $x metabolismus $7 D007136
650    _2
$a aktivace lymfocytů $7 D008213
650    _2
$a mutageneze cílená $7 D016297
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a RNA-polymerasa II $x genetika $x metabolismus $7 D012319
650    _2
$a somatická hypermutace imunoglobulinových genů $7 D027041
650    _2
$a genetická transkripce $7 D014158
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maman, Yaakov $u The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel
700    1_
$a Meng, Fei-Long $u Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA $u Department of Genetics, Harvard University, Boston, MA
700    1_
$a Kyläniemi, Minna K $u Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland $1 https://orcid.org/0000000173749862
700    1_
$a Soikkeli, Anni $u Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland
700    1_
$a Budzyńska, Paulina $u Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland $1 https://orcid.org/0000000228966806
700    1_
$a McDonald, Jessica J $u Department of Immunobiology, Yale School of Medicine, New Haven, CT; and $1 https://orcid.org/0000000258978947
700    1_
$a Šenigl, Filip $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Praha, Czech Republic
700    1_
$a Alt, Frederic W $u Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA $u Department of Genetics, Harvard University, Boston, MA $1 https://orcid.org/0000000205831271
700    1_
$a Schatz, David G $u Department of Immunobiology, Yale School of Medicine, New Haven, CT; and david.schatz@yale.edu jukka.alinikula@utu.fi $1 https://orcid.org/0000000256691176
700    1_
$a Alinikula, Jukka $u Unit of Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland; david.schatz@yale.edu jukka.alinikula@utu.fi $1 https://orcid.org/0000000199266439
773    0_
$w MED00002741 $t Journal of immunology (Baltimore, Md. : 1950) $x 1550-6606 $g Roč. 208, č. 1 (2022), s. 143-154
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34862258 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130018 $b ABA008
999    __
$a ok $b bmc $g 1789226 $s 1162711
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 208 $c 1 $d 143-154 $e 20211203 $i 1550-6606 $m The Journal of immunology $n J Immunol $x MED00002741
GRA    __
$a R01 AI127642 $p NIAID NIH HHS $2 United States
GRA    __
$a T32 AI007019 $p NIAID NIH HHS $2 United States
GRA    __
$a UL1 TR001863 $p NCATS NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace